Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
Identifieur interne : 001641 ( PubMed/Curation ); précédent : 001640; suivant : 001642Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
Auteurs : O. Rascol [France] ; U. Sabatini ; F. Chollet ; N. Fabre ; J M Senard ; J L Montastruc ; P. Celsis ; J P Marc-Vergnes ; A. RascolSource :
- Journal of neurology, neurosurgery, and psychiatry [ 0022-3050 ] ; 1994.
English descriptors
- KwdEn :
- Adult, Aged, Analysis of Variance, Brain Mapping, Cerebral Cortex (blood supply), Cerebral Cortex (diagnostic imaging), Cerebral Cortex (drug effects), Cerebral Cortex (physiopathology), Cerebrovascular Circulation (drug effects), Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Movement (physiology), Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Time Factors, Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , therapeutic use : Levodopa.
- blood supply : Cerebral Cortex.
- diagnostic imaging : Cerebral Cortex, Parkinson Disease.
- drug effects : Cerebral Cortex, Cerebrovascular Circulation.
- drug therapy : Parkinson Disease.
- physiology : Movement.
- physiopathology : Cerebral Cortex, Parkinson Disease.
- Adult, Aged, Analysis of Variance, Brain Mapping, Female, Humans, Male, Middle Aged, Time Factors, Tomography, Emission-Computed, Single-Photon.
Abstract
Regional cerebral blood flow (rCBF) changes in cortical motor areas were measured during a movement of the dominant right hand in 15 patients with Parkinson's disease deprived of their usual levodopa treatment, in 11 patients with Parkinson's disease undergoing long-term treatment with levodopa, and in 15 normal volunteers. The supplementary motor areas were significantly activated in the normal subjects and in the patients receiving levodopa but not in the patients deprived of levodopa. The contralateral primary sensory motor area was significantly activated in all three groups. The ipsilateral primary sensory motor cortex was not activated in the normal subjects and the non-treated patients but was in the patients treated with levodopa. It is concluded that the supplementary motor area hypoactivation which is observed in akinetic non-treated patients with Parkinson's disease is not present in patients undergoing long-term treatment with levodopa. This result suggests that (a) levodopa improves the functional activity of supplementary motor areas in Parkinson's disease and (b) there is no pharmacological tolerance to this effect. The ipsilateral primary motor cortex activation observed in the patients treated with levodopa could be related to levodopa-induced abnormal involuntary movements.
PubMed: 8201325
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001682
Links to Exploration step
pubmed:8201325Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, Faculty of Medicine, National Institute of Health and Medical Research, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Medical and Clinical Pharmacology, Faculty of Medicine, National Institute of Health and Medical Research, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name></author><author><name sortKey="Chollet, F" sort="Chollet, F" uniqKey="Chollet F" first="F" last="Chollet">F. Chollet</name></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Celsis, P" sort="Celsis, P" uniqKey="Celsis P" first="P" last="Celsis">P. Celsis</name></author><author><name sortKey="Marc Vergnes, J P" sort="Marc Vergnes, J P" uniqKey="Marc Vergnes J" first="J P" last="Marc-Vergnes">J P Marc-Vergnes</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:8201325</idno><idno type="pmid">8201325</idno><idno type="wicri:Area/PubMed/Corpus">001682</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001682</idno><idno type="wicri:Area/PubMed/Curation">001641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001641</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O" last="Rascol">O. Rascol</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Medical and Clinical Pharmacology, Faculty of Medicine, National Institute of Health and Medical Research, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratory of Medical and Clinical Pharmacology, Faculty of Medicine, National Institute of Health and Medical Research, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sabatini, U" sort="Sabatini, U" uniqKey="Sabatini U" first="U" last="Sabatini">U. Sabatini</name></author><author><name sortKey="Chollet, F" sort="Chollet, F" uniqKey="Chollet F" first="F" last="Chollet">F. Chollet</name></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N" last="Fabre">N. Fabre</name></author><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J M" last="Senard">J M Senard</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J L" last="Montastruc">J L Montastruc</name></author><author><name sortKey="Celsis, P" sort="Celsis, P" uniqKey="Celsis P" first="P" last="Celsis">P. Celsis</name></author><author><name sortKey="Marc Vergnes, J P" sort="Marc Vergnes, J P" uniqKey="Marc Vergnes J" first="J P" last="Marc-Vergnes">J P Marc-Vergnes</name></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A" last="Rascol">A. Rascol</name></author></analytic><series><title level="j">Journal of neurology, neurosurgery, and psychiatry</title><idno type="ISSN">0022-3050</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Analysis of Variance</term><term>Brain Mapping</term><term>Cerebral Cortex (blood supply)</term><term>Cerebral Cortex (diagnostic imaging)</term><term>Cerebral Cortex (drug effects)</term><term>Cerebral Cortex (physiopathology)</term><term>Cerebrovascular Circulation (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Movement (physiology)</term><term>Parkinson Disease (diagnostic imaging)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Time Factors</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="blood supply" xml:lang="en"><term>Cerebral Cortex</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Cerebral Cortex</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cerebral Cortex</term><term>Cerebrovascular Circulation</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Movement</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Analysis of Variance</term><term>Brain Mapping</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Regional cerebral blood flow (rCBF) changes in cortical motor areas were measured during a movement of the dominant right hand in 15 patients with Parkinson's disease deprived of their usual levodopa treatment, in 11 patients with Parkinson's disease undergoing long-term treatment with levodopa, and in 15 normal volunteers. The supplementary motor areas were significantly activated in the normal subjects and in the patients receiving levodopa but not in the patients deprived of levodopa. The contralateral primary sensory motor area was significantly activated in all three groups. The ipsilateral primary sensory motor cortex was not activated in the normal subjects and the non-treated patients but was in the patients treated with levodopa. It is concluded that the supplementary motor area hypoactivation which is observed in akinetic non-treated patients with Parkinson's disease is not present in patients undergoing long-term treatment with levodopa. This result suggests that (a) levodopa improves the functional activity of supplementary motor areas in Parkinson's disease and (b) there is no pharmacological tolerance to this effect. The ipsilateral primary motor cortex activation observed in the patients treated with levodopa could be related to levodopa-induced abnormal involuntary movements.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8201325</PMID><DateCreated><Year>1994</Year><Month>07</Month><Day>07</Day></DateCreated><DateCompleted><Year>1994</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3050</ISSN><JournalIssue CitedMedium="Print"><Volume>57</Volume><Issue>5</Issue><PubDate><Year>1994</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J. Neurol. Neurosurg. Psychiatr.</ISOAbbreviation></Journal><ArticleTitle>Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.</ArticleTitle><Pagination><MedlinePgn>567-71</MedlinePgn></Pagination><Abstract><AbstractText>Regional cerebral blood flow (rCBF) changes in cortical motor areas were measured during a movement of the dominant right hand in 15 patients with Parkinson's disease deprived of their usual levodopa treatment, in 11 patients with Parkinson's disease undergoing long-term treatment with levodopa, and in 15 normal volunteers. The supplementary motor areas were significantly activated in the normal subjects and in the patients receiving levodopa but not in the patients deprived of levodopa. The contralateral primary sensory motor area was significantly activated in all three groups. The ipsilateral primary sensory motor cortex was not activated in the normal subjects and the non-treated patients but was in the patients treated with levodopa. It is concluded that the supplementary motor area hypoactivation which is observed in akinetic non-treated patients with Parkinson's disease is not present in patients undergoing long-term treatment with levodopa. This result suggests that (a) levodopa improves the functional activity of supplementary motor areas in Parkinson's disease and (b) there is no pharmacological tolerance to this effect. The ipsilateral primary motor cortex activation observed in the patients treated with levodopa could be related to levodopa-induced abnormal involuntary movements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Laboratory of Medical and Clinical Pharmacology, Faculty of Medicine, National Institute of Health and Medical Research, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabatini</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Chollet</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fabre</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Montastruc</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Celsis</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Marc-Vergnes</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neurology. 1967 May;17(5):427-42</RefSource><PMID Version="1">6067254</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cereb Blood Flow Metab. 1993 Jul;13(4):639-45</RefSource><PMID Version="1">8314917</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1984 Feb;4(2):539-60</RefSource><PMID Version="1">6199485</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 1984 May;51(5):1109-20</RefSource><PMID Version="1">6610024</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1984 May 21;300(1):63-81</RefSource><PMID Version="1">6733468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1985 Mar;108 ( Pt 1):171-91</RefSource><PMID Version="1">3978397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1985 Mar;17(3):303-5</RefSource><PMID Version="1">3873210</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rev Neurol (Paris). 1985;141(5):413-5</RefSource><PMID Version="1">4048732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52</RefSource><PMID Version="1">2841426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 1986;1(4):255-66</RefSource><PMID Version="1">3504248</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 1989 Feb;112 ( Pt 1):233-44</RefSource><PMID Version="1">2917279</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:78-89</RefSource><PMID Version="1">2666581</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1990 Jul 7;336(8706):32-4</RefSource><PMID Version="1">1973218</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 1990 Jul;13(7):266-71</RefSource><PMID Version="1">1695401</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1990 Oct 27;336(8722):1028-30</RefSource><PMID Version="1">1977019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1991 Jan;29(1):63-71</RefSource><PMID Version="1">1996881</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 1991;84(2):393-402</RefSource><PMID Version="1">2065746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 1991 Aug;32(2):229-34</RefSource><PMID Version="1">1931472</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 1992 Feb;49(2):144-8</RefSource><PMID Version="1">1736846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992 May;31(5):463-72</RefSource><PMID Version="1">1596081</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992 Aug;32(2):151-61</RefSource><PMID Version="1">1510355</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1992 Dec;32(6):749-57</RefSource><PMID Version="1">1471865</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Comput Assist Tomogr. 1981 Oct;5(5):641-5</RefSource><PMID Version="1">6975286</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="N">Cerebrovascular Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC1072916</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8201325</ArticleId><ArticleId IdType="pmc">PMC1072916</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001641 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001641 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:8201325
|texte= Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:8201325" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |